Redhill Biopharma (RDHL)

• Market cap: $4.27M
• 1 day: -1.2%
• 5 days: -20.28%
• 1 month: -12.32%
• 3 months: -15.59%
• 6 months: -44.76%
• Year to date: -31.89%
• 1 year: -66.44%
• 5 years: -99.99%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Employees: 23